Radiopharmaceutical therapy is forcing oncology to rethink what a “dose” actually means. Unlike conventional drugs, the amount of radioactive material administered to a patient does not necessarily tell physicians how much radiation ultimately reaches the tumor or surrounding organs, creating a fundamental challenge for how radiopharmaceutical therapies are developed, tested and optimized.
That issue was the focus of a September 15 webinar hosted byFriends of Cancer Researchand an accompanyingwhite paper on optimizing dosing for radiopharmaceutical therapies. The report argues that administered activity, absorbed dose, clinical response and toxicity need to be evaluated together rather than assuming that increasing the amount injected will translate predictably into greater tumor radiation or greater therapeutic benefit.
In radiopharmaceutical therapy, administered activity refers to the quantity of radioactivity given to the patient, typically measured in gigabecquerels or millicuries. Absorbed dose, measured in gray, reflects how much radiation energy is actually deposited in a particular tumor, organ or tissue.
Those two measurements are related, but they are not interchangeable. Differences in tumor burden, target expression, biodistribution, organ function, clearance and patient biology can all influence where a radiopharmaceutical goes after it enters the body and how long it remains there, meaning two patients receiving the same administered activity can experience different radiation exposures in both tumors and healthy organs.
That creates a challenge for drug developers because administered activity is relatively easy to control, while absorbed dose can be much harder to measure and predict. Early clinical studies often have to escalate treatment before the relationship among administered activity, absorbed dose, response and toxicity is fully understood.
Another problem is historical. Radiopharmaceutical developers have often used organ radiation limits derived from external-beam radiation therapy as reference points when determining how aggressively activity can be escalated.
The Friends white paper argues that those limits can provide useful safety context, but they were developed for a very different type of radiation exposure. External-beam therapy typically delivers radiation from outside the body in controlled fractions over a relatively short period, while radiopharmaceutical therapies circulate systemically and can expose tumors and healthy tissues to radiation over hours or days.
Treatment cycles may also be separated by weeks, allowing different degrees of tissue recovery between administrations. The report argues that external-beam-derived limits should therefore be treated as reference points rather than fixed boundaries that automatically determine how much radiopharmaceutical therapy a patient can receive.
The emerging approach is much more multidimensional. Instead of optimizing only the amount of radioactivity administered per treatment, developers may need to consider the number of cycles, interval between treatments, cumulative administered activity, absorbed dose, ligand mass and changes in the patient over time.
The white paper recommends combining dosimetry with imaging, safety data, pharmacokinetics, biological markers and clinical outcomes to build a clearer picture of the therapeutic index. Representatives fromRayzeBio, Ratio Therapeutics, Novartis, Mayo Clinic,AstraZenecaandEli Lillyparticipated in the discussion, reflecting how broadly the issue now cuts across radiopharmaceutical development.
The objective is not necessarily to perform extensive personalized dosimetry for every patient in every clinical trial. Rather, the proposed framework calls for collecting enough information during development to understand how the administered drug translates into radiation exposure, therapeutic response and toxicity for the specific radiopharmaceutical being studied.
The dosing question becomes even more important as radiopharmaceutical therapies move into larger and potentially earlier patient populations. A treatment developed initially in heavily pretreated patients may behave differently when used in people with lower tumor burden, better organ function or longer expected survival, particularly when delayed or cumulative toxicities become more relevant.
That means the dose selected during an early clinical program may not necessarily remain optimal across every stage of disease. As developers accumulate more imaging, dosimetry and outcome data, treatment regimens could increasingly be refined around patient characteristics and biological response rather than relying primarily on a fixed administered activity.
This would represent a significant evolution from the standardized dosing schedules used by many radiopharmaceutical therapies today. It could also make nuclear medicine more central to treatment planning because imaging and dosimetry would not simply confirm where a drug went; they could help determine how much therapy should be given next.
For pharmaceutical companies, this creates both a scientific challenge and a development opportunity. Optimizing radiopharmaceutical therapy may require closer integration between drug development, nuclear medicine, medical physics, imaging and radiation biology than is typical for conventional oncology drugs.
It could also affect clinical trial design. Developers may need to collect more longitudinal imaging and dosimetry data, evaluate multiple administered activity levels and schedules, and follow patients long enough to detect toxicities that emerge after several treatment cycles rather than during the traditional early dose-limiting toxicity window.
The broader implication is that radiopharmaceutical therapy may ultimately demand a more sophisticated definition of dosing than oncology has historically used. The amount of radioactive drug placed into the syringe is easy to measure, but what matters clinically is what happens after that drug enters the patient.
